AVBP

Analyst Note: ArriVent BioPharma, Inc. (AVBP)

Date: June 20, 2026 Event Date: 2026-06-20

1. Structural Readiness

Conservative Entry: $27.25 Current Price: $31.74 Extension: +16.5% vs. conservative entry Breakout Level: $27.25 (Conservative Entry)

2. The Thesis Layer

Primary Secular Thesis: Biotech & GLP-1 → Oncology (Tier Direct, Confidence High). Thesis Exposure: ArriVent BioPharma is a direct beneficiary of the secular demand for next-generation oncology therapies, specifically targeting non-small cell lung cancer (NSCLC). The company is positioned to address a critical unmet need in the EGFR-mutated NSCLC market, a segment characterized by high prevalence and significant mortality rates.

The company's role is that of a developer and commercializer of novel small molecules and ADCs (Antibody-Drug Conjugates) for global markets (excluding Greater China). The thesis is strengthened by the company's focus on "uncommon" mutations (Exon 20 insertions and PACC mutations) which are currently underserved by existing standard-of-care treatments. The alignment with the "Biotech & Oncology" theme is direct, as the company's entire pipeline is dedicated to treating lung cancer, a disease imposing a massive global health burden with an estimated 2.2 million new cases and 1.8 million deaths annually.

3. The Business

Business Model & Industry: ArriVent BioPharma operates as a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecules and antibody-drug conjugates (ADCs) for oncology. The company utilizes a partnership-heavy model, leveraging licensing agreements to expand its pipeline while retaining commercial rights outside of Greater China.

Key Operations & Evidence (as of June 20, 2026):

• Core Asset (Firmonertinib): The company is conducting pivotal Phase 3 clinical trials for firmonertinib.
• FURVENT Trial: As of March 2026, the company enrolled 398 patients in the FURVENT trial, a global, pivotal Phase 3 study for firmonertinib in first-line non-squamous locally advanced or metastatic NSCLC patients with exon 20 insertion mutations (Evidence E9).
• ALPACCA Trial: In December 2025, the company announced the first patient dosed in the ALPACCA trial, planning to enroll 480 patients for firmonertinib in first-line patients with PACC mutations (Evidence E10).
• New Partnership: In March 2026, ArriVent dosed its first patient in an ongoing Phase 1 study in partnership with Lepu Biopharma (Evidence E2).
• Commercialization & Licensing:
• China Rights: Firmonertinib is currently approved and commercially distributed by Shanghai Allist Pharmaceuticals Co. Ltd. (Allist) in China for classical EGFRm NSCLC and recently received accelerated approval for second-line therapy for EGFRm exon 20 NSCLC (Evidence E4, E11).
• Global Rights: ArriVent holds the rights to develop and commercialize firmonertinib worldwide, excluding Greater China, under an agreement entered into in 2021 (Evidence E12).
• New Asset (ARR-217): In January 2025, the company entered an Exclusive License Agreement with Lepu Biopharma to develop and commercialize ARR-217 (MRG007), a CD-H17-targeting ADC for gastrointestinal cancers outside Greater China (Evidence E15).
• Financial Position:
• As of March 31, 2026, the Company reported an aggregate balance of cash, cash equivalents, and marketable securities of $326.4 million. Management concluded this balance is sufficient to sustain planned operations for at least twelve months from the issuance date of the financial statements (Evidence E3).
• Milestone Obligations:
• The Company has obligations to make future milestone payments to Allist of up to $105.0 million in clinical/regulatory milestones and up to $655.0 million in commercial milestones (Evidence E7).
• The Company is obligated to pay Lepu milestone payments up to an aggregate of approximately $1.17 billion upon the achievement of certain development, regulatory, and sales milestones (Evidence E8).

4. Archetype and Conviction

Archetype: Growth Leader / Clinical Catalyst Valuation & Conviction Context: ArriVent fits the "Growth Leader" archetype within the biotech sector, driven by the progression of its clinical pipeline rather than current revenue generation. The company is in a high-conviction phase where the primary value driver is the successful execution of its Phase 3 trials (FURVENT and ALPACCA) and the subsequent regulatory approvals.

• Thesis Strength: High. The focus on EGFRm NSCLC with uncommon mutations addresses a clear, high-value market gap.
• Evidence Quality: Strong. The evidence base includes specific enrollment numbers (398 and 480 patients), clear trial names, and confirmed cash runway through mid-2027.
• Structural Quality: The ATR at breakout (6.4%) indicates a "Very High" volatility environment, which is consistent with biotech catalysts. The current ATR of 5.2% remains in the "High" bucket, suggesting the stock is actively trading on news flow or technical momentum.
• Rerating Potential: Significant. Successful Phase 3 readouts or regulatory approvals in the EGFRm space could trigger a substantial re-rating, especially given the potential for $1.17 billion in future milestone payments from Lepu and $655 million from Allist, which would validate the commercial viability of the assets.

5. Invalidation, Strengthening, and Gaps

Invalidation Factors:

• Clinical Failure: Any announcement of negative top-line data from the FURVENT or ALPACCA Phase 3 trials would fundamentally invalidate the growth thesis.
• Cash Runway Breach: If the $326.4 million cash balance (as of March 31, 2026) is depleted before the completion of trials or if management announces a need for dilutive financing, the setup would be invalidated.

Strengthening Factors:

• Positive Data Readouts: Announcements of positive interim or top-line data from the Phase 3 trials.
• Regulatory Milestones: Receipt of accelerated approval or Fast Track designation from the FDA or EMA.
• Strategic Partnerships: New licensing deals or collaborations that provide upfront cash or reduce the net cost of development.

Gaps in Evidence:

• Specific Trial End Dates: While enrollment numbers and start dates are provided, the specific expected completion dates for the Phase 3 trials are not explicitly detailed in the provided evidence, creating uncertainty on the timing of catalysts.
• Detailed Financial Projections: The evidence provides a cash balance but lacks specific revenue projections or detailed burn rate analysis beyond the "sufficient for twelve months" statement.
• Competitive Landscape Data: While the unmet need is described, specific comparative data on how firmonertinib performs against the latest competing therapies in the market is not provided in the evidence block.

PRIVATE ANALYST CALL Judgment: Buy Confidence: high Key risks: Clinical trial failure in Phase 3; potential need for dilutive capital if cash burn accelerates; high milestone payment obligations to partners ($1.17B to Lepu, $655M to Allist) impacting future margins. Sizing hint: Position size should reflect the high ATR (5.2%) and the binary nature of clinical catalysts; standard risk management applies. Expected path: Management expects to complete enrollment and achieve top-line data for FURVENT and ALPACCA, followed by regulatory submissions and potential approvals, driving commercialization via Allist in China and ArriVent globally. Expected horizon: 12 to 24 months for key clinical data readouts and regulatory decisions.